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Background: Anal squamous cell carcinoma with lymph node metastases carries a poor outcome. There
remains a need for a better method to diagnose inguinal lymph node metastases which is minimally
invasive, accurate and avoids unnecessary irradiation to the groin with its associated signiﬁcant co-
morbidity. The aim of this study was to evaluate the role of sentinel lymph node (SLN) biopsy in anal
squamous cell carcinoma.
Methods: The systematic review was conducted in accordance with PRISMA guidelines. The Medline,
Central and Embase databases were searched using the terms ‘sentinel lymph node’ and ‘anus
neoplasms’.
Results: The systematic review identiﬁed 17 studies, containing 270 patients. SLN detection rate varied
from 47% to 100%. The presence of nodal metastases varied from 0 to 44%. The complication rate varied
from 0 to 59%. The rate of development of subsequent inguinal lymph node metastases in those previ-
ously SLN biopsy-negative (a surrogate marker for false negative rate) ranged from 0 to 18.75%.
Conclusion: SLN biopsy is a feasible method of assessing lymph node status in patients with anal squa-
mous cell carcinoma. Longer follow up is required to evaluate the proportion of patients who are SLN
biopsy-negative and subsequently develop nodal metastases. More studies are required to ascertain
whether SLN biopsy should be the main method of assessing inguinal lymph node involvement in pa-
tients with anal squamous cell carcinoma.
 2013 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Anal squamous cell carcinoma is an uncommon malignancy,
accounting for approximately 4% of all gastrointestinal malig-
nancies.1 Metastases to superﬁcial inguinal lymph nodes occur in
15e25% of cases in T1/T2 carcinoma and up to 50% of T3/T4 carci-
noma.2 Lymph node involvement has been shown to be a negative
prognostic indicator for survival, yet detecting positive lymph
nodes remains a challenge.3 In particular there is no consensus
regarding the optimal management of patients with anal squamous
cell carcinoma and clinically uninvolved inguinal lymph nodes.
Since the work of Nigro and colleagues in 1974, chemo-
radiotherapy has replaced abdominoperineal excision of the
rectum as the ﬁrst line treatment of anal squamous cell carcinoma.4Addenbrooke’s Hospital, Hills
k (R.J. Davies).
ciates Ltd. Published by Elsevier LtProphylactic radiotherapy to the groin has been shown to reduce
the rate of inguinal lymph node metastasis from 4 to 25%.5 How-
ever, signiﬁcant radiotherapy related morbidity occurs in around
15% of all patients; short term complications include erythema and
skin burns, with small bowel damage, hip fractures, bladder injury
and sexual dysfunction being more problematic in the long term.6,7
The diagnostic dilemma remains in detecting lymph node meta-
stastes in these patients in order to tailor treatment to the indi-
vidual, and avoid potential over treatment in thosewith uninvolved
nodes.
Wade and colleagues demonstrated that 44% of all lymph node
metastases are <5 mm in diameter and not detectable by con-
ventional imaging.8 Ultrasound remains variable with a sensitivity
of 36e87% and speciﬁcity of 56e89%.9 Ultrasound with ﬁne needle
aspiration (FNA) also has a low detection rate at 65%.10 Recently,
positron emission tomography (PET) imaging has been shown to
detect inguinal metastases in up to 20% of patients who have
clinically and radiologically uninvolved nodes on conventional
imaging.11 There remains a clear need for a more accurate methodd. All rights reserved.
Figure 1. Flow diagram of screening and selection of articles for the systematic review.
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alize treatment of patients with anal squamous cell anal carcinoma,
and avoid unnecessary morbidity from prophylactic groin
radiotherapy.
The sentinel lymph node (SLN) concept was ﬁrst described in
1960 in parotid cancer.12 It was clinically implemented by Cabanas
in 1977 in penile cancer.13 Its role in breast cancer and melanoma
has been investigated, but its role in gastrointestinal cancers is less
clear.14,15 Two techniques are most commonly used for SLN biopsy
in anal cancer. The ﬁrst involves lymphoscintigraphy to identify
lymphatic drainage and the ﬁrst node in which the tracer is
captured. The radioisotope, commonly a technetium-labelled
nanocolloid, is injected around the anal tumour and the node is
localised using a gamma camera. During surgery, a hand-held
gamma probe is used to detect the presence of the radioisotope.
The second technique involves injection of blue dye around the site
of the tumour during surgery. This visually aids the detection of the
SLN, and the two techniques may be used individually or in com-
bination. Excision of the node can be performed under local or
general anaesthesia, and the excised node(s) is sent forTable 1
Results of systematic review.
Author No. patients Year Dye vs
isotope
No of patients
having SLN
biopsy
SLN ide
De Jonga25 50 2011 Both 21 21/21 ¼
Peley19 8 2002 Both 8 8/8 ¼ 1
Bobin18 33 2003 Both 33 33/33 ¼
Perera20 12 2003 Both 12 8/12 ¼
Damin21 14 2003 Both 14 14/14 ¼
Ulmer31 12 2003 Isotope 12 10/12 ¼
Mistrangelo23 35 2008 Isotope 34 34/35 ¼
Gretschel22 40 2008 Isotope 20 20/20 ¼
Rabbit29 4 2002 Both 4 4/4 ¼ 1
Ulmer17 17 2004 Isotope 13 13/17 ¼
Castro33 2 2005 Both 2 2/2 ¼ 1
Francois32 34 2010 Isotope 34 16/34 ¼
De Nardi24 11 2011 Both 9 9/9 ¼ 1
Mistrangelo26 27 2010 Both 27 27/27 ¼
Hirche27 12 2010 Both 12 9/12 ¼
Mistrangelo30 15 2005 Isotope 15 15/15 ¼
Keshtgar28 1 2001 Both 1 1/1 ¼ 1histopathological analysis using either frozen section or parafﬁn-
block sections.
The aim of this systematic review was to investigate the role of
SLN biopsy in anal squamous cell carcinoma.2. Methods
A systematic reviewwas conducted in accordancewith the PRISMA guidelines.16
The terms ‘sentinel lymph node’ and ‘anus neoplasms’ were used to search Embase,
Central and Medline databases by two independent researchers (AN and NR).
Conference proceedings from major general surgery meetings (Association of Sur-
geons of Great Britain and Ireland, American Society of Colon and Rectal Surgeons,
European Society of Coloproctology, Association of Coloproctology of Great Britain
and Ireland and American College of Surgeons Annual Congress) were searched from
2000 to 2011. Any identiﬁed abstracts were scrutinised to determine eligibility for
inclusion. Reference lists from eligible reports were also searched for potential
abstracts.
The quality of studies was assessed using the Down and Black checklist for both
randomised and non-randomised studies.17 A total of 27 questions assess each paper
on quality of reporting, external validity and internal validity (bias and confounding
factors). The maximum a study can score is 27 as one point is given to each satisﬁed
criterion of the checklist. This checklist provides a proﬁle of the publication and
helps reviewers identify its strengths and weaknesses. Two reviewers (AN and NR)
scored studies independently and a kappa statistic was calculated to assess inter-
rater variability using Stats Direct (Stats Direct Ltd, Altrincham, UK). Any differ-
ence in score was re-assessed by an independent reviewer (SRW).
Studies were eligible for inclusion provided they met the following criteria:
subjects aged 18 or over and at least one clinical outcome reported by authors.
Studies were excluded if they included anal melanoma or subjects with clinically
palpable inguinal lymph nodes.
The primary outcome was SLN detection (positive SLN/total number patients
undergoing SLN biopsy). The secondary outcomes were nodal metastases (SLN
nodes positive for metastases/total SLNs identiﬁed) and nodal metastases in SLN
biopsy-negative patients during follow up (false negative rate). Data were entered
into an Excel (Microsoft Excel, Redmond, USA) Spreadsheet for analysis.3. Results
The search results are presented in Fig. 1 in the format of the
PRISMA guidelines. A total of 17 studies were eligible,17e34 equating
to a sum of 270 patients. Table 1 summarises the results. Sentinel
lymph node detection and nodal metastases were reported by all
studies.
Table 2 summarises the Down and Black score for each study,
and provides a detailed breakdown of the component of the score.
The maximum score for each of the subdivisions was 10 for quality
of reporting, 3 for external validity, 7 for internal validityntiﬁed Nodal metastasis
(SLNþSLN identiﬁed)
Nodal metastasis in SLN
biopsy-negative patients
during follow up (%)
Down and
black score
100% 7/21 ¼ 33% 9.5% 17
00% 2/8 ¼ 25% No Follow up 16
100% 7/33 ¼ 21% 0% 17
67% 2/12 ¼ 17% No follow up 12
100% 1/14 ¼ 7% No follow up 19
80% 4/9 ¼ 44% No follow up 16
97% 7/34 ¼ 21% 0% 18
100% 6/20 ¼ 30% 10% 18
00% 0/4 ¼ 0% No follow up 8
77% 5/12 ¼ 42% Not stated 18
00% 0/2 ¼ 0% No follow up 7
47% 5/16 ¼ 31% 18.75% Not scored as
abstract only.
00% 3/9 ¼ 33% No follow up 15
100% 3/27 ¼ 11% 0% 23
75% 2/9 ¼ 22% 0% 18
100% 5/14 ¼ 27% No Follow up 18
00% 0/1 ¼ 0% No Follow up 7
Table 2
Down and Black scores for each study.
Study Year Quality of reporting
(Max score ¼ 10)
External validity
(Max score ¼ 3)
Internal validity: bias
(Max score ¼ 7)
Internal validity: confounding
factors (Max score ¼ 7)
Total score
(Max score ¼ 27)
De Jonga25 2011 7 3 4 3 17
Peley19 2002 7 3 5 1 16
Bobin18 2003 8 3 4 2 17
Perera20 2003 5 3 2 2 12
Damin21 2003 8 3 5 3 19
Ulmer17 2004 7 3 5 1 16
Mistrangelo23 2008 8 3 4 3 18
Gretschel22 2008 8 3 5 2 18
Rabbit29 2002 5 2 1 0 8
Ulmer31 2003 6 3 4 5 18
Castro33 2005 3 2 2 0 7
Francois32 2010 Not scored Not scored Not scored Not scored Not scored
De Nardi24 2011 8 3 3 1 15
Mistrangelo26 2010 10 3 5 5 23
Hirche27 2010 8 3 5 2 18
Mistrangelo30 2005 5 3 4 6 18
Keshtgar28 2001 3 2 2 0 7
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total maximum score that could be awarded to each manuscript
was 27.
The kappa statistic for inter-rater variability was 0.706 (SE 0.125,
95% CI 0.456e0.957) which demonstrated a ‘good’ agreement.
Table 3 summarises the complication rates for SLN biopsy. Six
studies described complications, with the highest rate reported at
59%.22,25e27,31 However, only two cases of the 46 complications
reported needed further intervention with the remainder
resolving with conservative management within 2 weeks. In
terms of long term follow up data, this was only recorded in 7
studies.
3.1. SLN detection
The results of this review demonstrate that the rate of SLN
detection varies from 47% to 100%. Damin et al. highlighted in an
earlier report that a lower rate of SLN detection was seen in studies
which used radioisotope alone, and that the detection rate was
much improved in studies which used radioisotope in combination
with blue dye.34 In this systematic review, the lower rate of SLN
detection of 47% was in a study by Francois and colleagues, which
used isotope alone.32 However other studies using isotope alone
had detection rates of 100%, hence superiority of either method
cannot be concluded. There is evidence in melanoma and breast
cancer, that combining the two methods results in a better overall
method of detecting the SLN38,39 and it may be that further studiesTable 3
Complications from sentinel lymph node biopsy.
Author Total
patients
Year Dye vs
isotope
No of patients
having SLN biopsy
Num
com
De Jong25 50 2010 Both 21 5/2
Mistrangelo23 35 2008 Isotope 34 20/
Gretschel22 40 2008 Isotope 20 4/2
Ulmer17 17 2003 Isotope 12 1/1
Hirche27 12 2010 Both 12 2/1
Mistrangelo26 27 2010 Isotope 27 14/are required beforewe canmake such deductions in anal squamous
cell carcinoma.
3.2. Nodal metastasis
The rate of nodal metastasis varied from 0%28,29,33e44%.17
Studies with nodal metastasis rate of 0% had very small subject
numbers, and this is likely to have contributed to their
results.28,29,33
3.3. False negative rate
It is not possible to accurately detect the sensitivity and speci-
ﬁcity of SLN biopsy, as to do this a surgical groin dissection would
be required in order to assess the true status of nodes which were
not detected using the SLN method. However another surrogate
marker for a false negative rate is to follow up SLN biopsy-negative
patients who did not undergo radiotherapy. This was done by seven
studies and the rate of development of subsequent inguinal lymph
node metastases ranged from 0 to 18.75%.18,22,23,25e27,32
4. Discussion
The rationale for SLN biopsy is to improve staging for anal
squamous cell carcinoma. As described, the most common SLN
biopsy techniques involve injection of radioisotope-labelled nano-
colloid with or without blue dye injection. More recently,ber of
plications
Types of complications Further intervention
required
1 ¼ 24% 2 wound infections
2 seromas
1 lymphoedema
No
34 ¼ 59% 1 lymphocoele requiring surgery
1 monolateral lymphoedema
18 inguinal lymphorrhoea
Yes (n ¼ 1)
0 ¼ 20% 2 wound infections
1 lymphatic ﬁstula
1 haematoma
No
2 ¼ 8% 1 cutaneous lymphatic ﬁstula No
2 ¼ 17% 1 lymphocoele, 1 lymphorrhoea No
27 ¼ 52% 13 ¼ inguinal lymphorrhoea
1 ¼ lymphocoele requiring evacuation
Yes (n ¼ 1)
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breast cancer,35 gastric cancer36 and anal cancer.27 This technique is
well established in breast cancer. However, its role in anal and
gastrointestinal malignancies requires further development. In
breast cancer, it has been shown to have acceptable sensitivity and
speciﬁcity.37 In addition it allows transcutaneous visualisation of
lymphatic vessesls and intraoperative lymph node detection
without the use of radioisotope. Regardless of the method, the aim
of SLN biopsy is to detect the presence of lymph nodemetastases in
draining lymph nodes, in order to more accurately stage the dis-
ease. This would help identify patients who would beneﬁt from
radiotherapy, regardless of its associated side effects and enable
patients with no evidence of involved inguinal nodes to be spared
the signiﬁcant morbidity associated with radiotherapy to the groin.
Recent studies have concentrated on the role of positron emis-
sion tomography (PET) in anal squamous cell carcinoma, either
alone or in combination with computer tomography (CT). Nguyen
et al. reported an upstaging in up to one ﬁfth of cases with PET-CT.40
Schwarz and colleagues reported improved survival in patients
with complete metabolic response on post-treatment PET imag-
ing.41 The only study to date to compare PET-CT to SLN biopsy is by
Mistrangelo et al.26 In this study of 27 patients, SLN biopsy was
found to be superior in staging squamous cell carcinoma of the
anus compared to PET-CT, mainly because of the high false positive
rate with PET-CT. Though PET-CT sensitivity was 100%, the false
positive rate resulted in a speciﬁcity of 83% and positive predictive
value was 43% .The SLN biopsy technique in this study resulted in
no false positive results. This is extremely relevant as accurate
detection of inguinal lymph node involvement is likely to prevent
unnecessary groin irradiation and its associated complications.
5. Limitations
There remain limited studies in the current literature. The total
number of patients included in this systematic review was 270 and
hence we could not perform any conclusive statistical tests to
further analyze the data. In particular we could not perform tests of
heterogeneity or bias.
In addition, none of the studies compared SLN biopsy to the gold
standard of groin dissection. These data would be required in order
to perform a quantitative meta-analysis and to calculate pooled
sensitivities and speciﬁcities of both methods. Until then, the su-
periority of one method over the other cannot be accurately
ascertained.
One study compared PET versus SLN biopsy.26 It was also un-
clear whether a similar cohort of patients had been used in a pre-
vious study.23 There was insufﬁcient evidence to suggest this.
Therefore, all three studies by Mistrangelo et al. were included.
A Down and Black score was calculated for each study. However
one study32 was an abstract only and hence could not be scored
accurately.
Studies were not randomised as the current literature on this
topic still needs further development. However, SLN biopsy appears
a feasible method for detection of inguinal nodal metastases, and
though complications exist, these are generally self limiting and
minor when compared to the complications of unnecessary groin
radiotherapy. Certainly further studies are required to assess the
false negative rate of SLN biopsy.
6. Conclusion
There remains a need for a more selective approach, to indi-
vidualize treatment regimens for patients with anal squamous cell
carcinoma. Sentinel lymph node biopsy may prove to be a useful
technique to help identify patients who will beneﬁt most fromgroin radiotherapy. However, further studies are required before
SLN biopsy has a proven role in routine daily practice of staging anal
cancer. Serious consideration should now be given to a randomized
trial of SLN biopsy versus no prophylactic inguinal radiotherapy,
with SLN biopsy-negative patients receiving no radiotherapy and a
“watch and wait” policy. Those who are SLN-positive should then
still receive groin radiotherapy.
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